Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Genta Genasense NDA In Myeloma Or Leukemia Slated For Year-End Filing

Executive Summary

Genta is shifting its Genasense development focus to multiple myeloma and chronic lymphocytic leukemia with the goal of submitting an NDA for one of the oncology indications by year-end

You may also be interested in...

Lilly Alimta Lung Cancer Use Supported By FDA Cmte.; Safety Profile Cited

The favorable toxicity profile of Lilly's oncologic Alimta outweighs uncertain survival benefits in the second-line treatment of non-small cell lung cancer, FDA's Oncologic Drugs Advisory Committee agreed July 27

Aventis, Genta To Meet With FDA After Genasense NDA Withdrawal

Aventis will participate in Genta's meeting with FDA following the withdrawal of the new drug application for Genasense

Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts